Laura Prendergast
Stock Analyst at Raymond James
(0.01)
# 4,551
Out of 4,944 analysts
7
Total ratings
14.29%
Success rate
-31.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Initiates: Outperform | $5 | $1.63 | +207.69% | 1 | Mar 26, 2025 | |
| MURA Mural Oncology | Initiates: Strong Buy | $18 | $1.79 | +905.59% | 1 | Oct 4, 2024 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $2.21 | +623.98% | 2 | Aug 14, 2024 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | $20 | $2.77 | +622.02% | 1 | Jul 31, 2024 | |
| RVMD Revolution Medicines | Upgrades: Strong Buy | $36 → $48 | $36.07 | +33.07% | 2 | Apr 10, 2024 |
Erasca
Mar 26, 2025
Initiates: Outperform
Price Target: $5
Current: $1.63
Upside: +207.69%
Mural Oncology
Oct 4, 2024
Initiates: Strong Buy
Price Target: $18
Current: $1.79
Upside: +905.59%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $2.21
Upside: +623.98%
Black Diamond Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: $20
Current: $2.77
Upside: +622.02%
Revolution Medicines
Apr 10, 2024
Upgrades: Strong Buy
Price Target: $36 → $48
Current: $36.07
Upside: +33.07%